There’s a difference between talking about fixing healthcare and actually wiring the system to work. House Rx isn’t talking. They’re coding, scaling, and putting muscle where bureaucracy still drags its feet. Founded by Ogi Kavazovic & Tesh Khullar, two ex-Flatiron Health execs who’ve lived every inefficiency in specialty care, the SF-based team just raised a $55M Series B led by New Enterprise Associates & Town Hall Ventures, with Bessemer Venture Partners, LRVHealth, First Round Capital & Silicon Valley Bank in the mix. That’s not a lineup, it’s conviction money stacked on execution.
When Kavazovic & Khullar launched House Rx in Mar 2021, the mission was clear: cut out the middlemen who turned getting critical meds into a waiting game. PBM-controlled mail-order pharmacies were great at one thing, delays. So House Rx built a model where specialty drugs are dispensed right inside the clinic, reconnecting physicians & pharmacists to deliver care in real time. No detours, no red tape, no please hold.
Fast-forward 4 yrs, 80 clinic sites nationwide, 1K+ prescribers, $1.2B in specialty prescriptions, serving nearly 61K patients. The results hit harder than any tagline: 85% med adherence vs. 70% industry avg, 92% first-pass approvals on prior auths, 3.5 days avg fill time vs. 15.5 days elsewhere. That’s not disruption, it’s design precision.
The engine driving this? An AI-enabled pharmacy management platform purpose-built for the complexity of specialty meds. It plugs directly into EHRs, automates prior auths in seconds, and brings real-time visibility to every stakeholder. Under CEO Ogi Kavazovic & Chief Pharmacy & Operating Officer Denali Cahoon, PharmD, with Product VP Salman Suhail steering the AI roadmap, House Rx plans to expand automation to 85% of workflows, scheduling, prescription intake, clinical documentation, the works.
This isn’t just health tech; it’s healthcare infrastructure getting an upgrade. While legacy PBMs play defense, House Rx is embedding pharmacists inside oncology & rheumatology practices from California to Tennessee, proving that local + tech beats central and slow every time.
This $55M round isn’t just capital, it’s confirmation. NEA & Town Hall Ventures aren’t gambling on a pitch deck; they’re doubling down on a correction the system’s been begging for. The specialty pharmacy market is worth $250B+, & House Rx just proved that clinically integrated, AI-powered care isn’t the next wave, it’s the tide already turning.
